Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine-SR Extension Study in Canadian MS Patients
NCT01235221Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalfampridine in multiple sclerosis (MS), sponsored by Biogen. Started Dec 2010; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01235221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235221.